Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Bambuterol in COPD
NCT01796730Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2013
- Primary completion
- Oct 2014
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bambuterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Forced Expiratory Volume in 1 Second at 11 weeks and Forced Vital Capacity at 11 weeks. Started Feb 2013; status: completed.
02
Drugs
bambuterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01796730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796730.